DaShenLin Pharmaceutical Group 大参林
12 significant filings since 30 May 2026: 2 on regulatory inquiry, 4 on dividend and 2 on guarantee or financial assistance, and 3 other kinds. The latest, on 25 Aug 2026: 大参林医药集团股份有限公司关于2026年半年度利润分配方案的公告.
自 30 May 2026 起有 12 份重大公告：regulatory inquiry 2 份、dividend 4 份、guarantee or financial assistance 2 份，另有 3 类。最新一份（25 Aug 2026）：大参林医药集团股份有限公司关于2026年半年度利润分配方案的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 2 Nov 2020 | 国金证券 | 王麟 | Outperform 增持 | ▲ | Buy 买入 |
| 28 Aug 2020 | 东莞证券 | 魏红梅,雷国轩 | Outperform 增持 | ▲ | Buy 买入 |
| 28 Aug 2020 | 国元证券 | 常启辉 | Outperform 增持 | ▲ | Buy 买入 |
| 6 May 2020 | 西南证券 | 朱国广,杜向阳 | Outperform 增持 | ▲ | Buy 买入 |
| 1 Nov 2019 | 民生证券 | 孙建 | Outperform 增持 | ▲ | Buy 买入 |
| 29 Jan 2019 | 中银国际 | 柴博,邓周宇 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,龙永茂 | Buy 买入 | 28 Aug 2026 | 3 | — |
| 东吴证券 | 朱国广,冉胜男,苏丰 | Buy 买入 | 26 Aug 2026 | 3 | — |
| 国信证券 | 陈曦炳,彭思宇,贾瑞祥 | Outperform 增持 | 25 Aug 2026 | 4 | — |
| 国金证券 | 甘坛焕,王奔奔 | Buy 买入 | 25 Aug 2026 | 3 | — |
| 信达证券 | 唐爱金,章钟涛 | Unrated | 27 Apr 2026 | 1 | — |
| 西南证券 | 杜向阳,汪翌雯 | Unrated | 14 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 2 of 15 reports. 每行为该券商近十二个月的最新研报；15 份中 2 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。